Gregory A. Durm

3.4k total citations · 1 hit paper
12 papers, 351 citations indexed

About

Gregory A. Durm is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gregory A. Durm has authored 12 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gregory A. Durm's work include Lung Cancer Treatments and Mutations (3 papers), Cancer survivorship and care (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Gregory A. Durm is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Cancer survivorship and care (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). Gregory A. Durm collaborates with scholars based in United States and Australia. Gregory A. Durm's co-authors include Shadia I. Jalal, Ahmed Bilal Khalid, Sandro Matosevic, Hirva Mamdani, Nasser H. Hanna, Adam T. Hirsh, Ekin Seçinti, Lawrence H. Einhorn, Catherine E. Mosher and Shelley A. Johns and has published in prestigious journals such as PLoS ONE, Journal of Controlled Release and Frontiers in Immunology.

In The Last Decade

Gregory A. Durm

11 papers receiving 349 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

2022 214 citations Hirva Mamdani, Sandro Matosevic et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gregory A. Durm United States	6	190	130	80	56	35	12	351
Julie Rowe United States	11	181 1.0×	113 0.9×	135 1.7×	47 0.8×	44 1.3×	30	495
Teresa Curiel Spain	9	149 0.8×	55 0.4×	85 1.1×	96 1.7×	37 1.1×	14	370
Jianwei Zheng China	12	112 0.6×	63 0.5×	122 1.5×	49 0.9×	61 1.7×	47	387
L. Jarolím Czechia	12	133 0.7×	109 0.8×	84 1.1×	136 2.4×	27 0.8×	41	527
Anh Gia Pham Vietnam	8	92 0.5×	44 0.3×	116 1.4×	28 0.5×	52 1.5×	17	378
Katsuya Hirano Japan	13	293 1.5×	272 2.1×	63 0.8×	19 0.3×	56 1.6×	51	512
Lay Cheng Lim Singapore	12	96 0.5×	51 0.4×	110 1.4×	29 0.5×	30 0.9×	23	417
Ana Collazo-Lorduy Spain	10	134 0.7×	73 0.6×	238 3.0×	47 0.8×	59 1.7×	20	556
Kiran A. Kumar United States	11	76 0.4×	88 0.7×	38 0.5×	65 1.2×	25 0.7×	47	373
Laundette P. Jones United States	9	168 0.9×	59 0.5×	152 1.9×	105 1.9×	108 3.1×	20	470

Countries citing papers authored by Gregory A. Durm

Since Specialization

Citations

This map shows the geographic impact of Gregory A. Durm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Durm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Durm more than expected).

Fields of papers citing papers by Gregory A. Durm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Durm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Durm. The network helps show where Gregory A. Durm may publish in the future.

Co-authorship network of co-authors of Gregory A. Durm

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Durm. A scholar is included among the top collaborators of Gregory A. Durm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Durm. Gregory A. Durm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Durm, Gregory A., DuyKhanh P. Ceppa, Shadia I. Jalal, et al.. (2025). Associations of health beliefs and worry with COVID-19 protective behaviors among lung cancer patients. Journal of Health Psychology. 30(11). 2927–2944.

Mamdani, Hirva, Sandro Matosevic, Ahmed Bilal Khalid, Gregory A. Durm, & Shadia I. Jalal. (2022). Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology. 13. 823618–823618. 214 indexed citations breakdown →

Seçinti, Ekin, Wei Wu, Adam T. Hirsh, et al.. (2022). Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making. Psycho-Oncology. 31(12). 2177–2184. 5 indexed citations

Elzey, Bennett D., et al.. (2022). Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO₄/Paclitaxel-Coloaded PEG-PLA Nanoparticles. Molecular Pharmaceutics. 19(8). 2776–2794. 10 indexed citations

Timsina, Lava, Gregory A. Durm, Shadia I. Jalal, et al.. (2021). Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence. PLoS ONE. 16(4). e0250285–e0250285. 4 indexed citations

Seçinti, Ekin, Wei Wu, Nasser H. Hanna, et al.. (2021). Measurement of patients’ acceptable symptom levels and priorities for symptom improvement in advanced lung cancer. Supportive Care in Cancer. 29(10). 5895–5904. 4 indexed citations

Gandara, David R., Kristen A. Marrone, Ramaswamy Govindan, et al.. (2021). Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 20(12_Supplement). P05–2. 15 indexed citations

Durm, Gregory A., et al.. (2020). 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A254.1–A254. 3 indexed citations

McClelland, Shearwood, Gregory A. Durm, Thomas J. Birdas, P. Musto, & Tim Lautenschlaeger. (2019). First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy. Reports of Practical Oncology & Radiotherapy. 24(6). 507–510. 1 indexed citations

10.

Mosher, Catherine E., Ekin Seçinti, Adam T. Hirsh, et al.. (2019). Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized Trial. Journal of Pain and Symptom Management. 58(4). 632–644. 67 indexed citations

11.

Misra, Rahul, Sandra Torregrosa‐Allen, Gregory A. Durm, et al.. (2019). Radioluminescent nanoparticles for radiation-controlled release of drugs. Journal of Controlled Release. 303. 237–252. 27 indexed citations

12.

Kiel, Patrick J., et al.. (2017). The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology. 8(6). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact